SILO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:13):

Stats
Today's Volume	197 255
Average Volume	195 258
Market Cap	5.29M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.580
ATR14	$0.0160 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Weisblum Eric	Buy	400	Common Stock
2024-04-04	Weisblum Eric	Buy	600	Common Stock
2024-04-01	Weisblum Eric	Buy	1 100	Common Stock
2024-03-28	Weisblum Eric	Buy	3 408	Common Stock
2023-12-20	Weisblum Eric	Buy	200	Common Stock

INSIDER POWER
100.00
Last 55 transactions
Buy: 22 165 052 \| Sell: 3 696 660

Volume Correlation

Long: 0.14 (neutral)

Short: 0.68 (moderate)

Signal:(65.792) Neutral

Silo Pharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Silo Pharma, Inc. Correlation - Currency/Commodity

-0.57
( weak negative )

-0.53
( weak negative )

0.00
( neutral )

-0.66
( moderate negative )

-0.67
( moderate negative )

-0.69
( moderate negative )

Silo Pharma, Inc. Financials

Annual	2023
Revenue:	$72 102.00
Gross Profit:	$-805 361 (-1 116.97 %)
EPS:	$-1.200

Q4	2023
Revenue:	$18 026.00
Gross Profit:	$-144 322 (-800.63 %)
EPS:	$-0.390

Q3	2023
Revenue:	$18 025.00
Gross Profit:	$16 566.00 (91.91 %)
EPS:	$-0.210

Q2	2023
Revenue:	$18 025.00
Gross Profit:	$16 566.00 (91.91 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Silo Pharma, Inc.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.